An Interview with Stephanie Planque of Covalent Bioscience

Source https://www.fightaging.org/archives/2023/04/an-interview-with-stephanie-planque-of-covalent-bioscience/

Covalent Bioscience develops catalytic antibodies, a way to bind and neutralize target molecules in the body without consuming the antibody molecule itself. A given dose of catalytic antibody can thus remove many times more target molecules than is the case for standard monoclonal antibodies. This offers the potential for highly efficient removal of age-related amyloids present outside cells, perhaps the most interesting of the many possible use cases, such as those related to suppression of specific signal molecules. Like most biotech companies, the backstory behind the science emphasizes the point that progression of any given technology from academia to industry is slow indeed.

…

What Do You Think?

comments